Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog

Stock Information for Chiasma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Chiasma Inc.

Pulmatrix appoints Director Anand Varadan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates WRI, WBT, CHMA, XOG, USCR, ONEM; Shareholders are Encouraged to Contact the Firm
SHAREHOLDER ALERT: WeissLaw LLP Reminds ONEM, BOCH, CHMA, and MDCA Shareholders About Its Ongoing Investigations
INVESTIGATION ALERT: Halper Sadeh LLP Investigates ONEM, SYKE, NETE, CHMA, SOLY, ARPO; Shareholders are Encouraged to Contact the Firm
SHAREHOLDER ALERT: WeissLaw LLP Reminds BOCH, PLBN, CORE, and CHMA Shareholders About Its Ongoing Investigations
INVESTIGATION ALERT: Halper Sadeh LLP Investigates HGV, CHMA, ONDS, BOCH; Shareholders are Encouraged to Contact the Firm
SHAREHOLDER ALERT: WeissLaw LLP Reminds BOCH, PLBN, CORE, and CHMA Shareholders About Its Ongoing Investigations
Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines Agency

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.